| Acne Vulgaris
Absorica vs Altreno
Side-by-side clinical, coverage, and cost comparison for acne vulgaris.Deep comparison between: Absorica Ld vs Altreno with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAltreno has a higher rate of injection site reactions vs Absorica Ld based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Altreno but not Absorica Ld, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Absorica Ld
Altreno
At A Glance
Oral
Twice daily
Retinoid
Topical
Daily
Retinoid
Indications
- Acne Vulgaris
- Acne Vulgaris
Dosing
Acne Vulgaris ABSORICA: 0.5 to 1 mg/kg/day in two divided doses for 15 to 20 weeks (up to 2 mg/kg/day for severe disease with scarring or trunk involvement); ABSORICA LD: 0.4 to 0.8 mg/kg/day in two divided doses for 15 to 20 weeks (up to 1.6 mg/kg/day for severe disease).
Acne Vulgaris Apply a thin layer to the affected areas once daily; avoid the eyes, mouth, paranasal creases, and mucous membranes.
Contraindications
- Pregnancy
- Hypersensitivity to isotretinoin, Vitamin A (given chemical similarity), or any component of the product
—
Adverse Reactions
Most common Cheilitis, hypertriglyceridemia, dry skin, dry lips, fatigue, headache, epistaxis, arthralgia, back pain, musculoskeletal pain
Serious Embryo-fetal toxicity, psychiatric disorders (including suicidal ideation, depression, psychosis), intracranial hypertension, serious skin reactions, pancreatitis, hepatotoxicity, inflammatory bowel disease, musculoskeletal abnormalities, hearing impairment, hypersensitivity reactions
Most common (>=1%) Application site dryness, pain, erythema, irritation, exfoliation
Pharmacology
Isotretinoin is a retinoid that inhibits sebaceous gland function and keratinization; clinical improvement in nodular acne is associated with a reduction in sebum secretion, reflecting reduced sebaceous gland size and inhibition of sebaceous gland differentiation.
Retinoid; topical tretinoin binds retinoic acid nuclear receptors (RARalpha, RARbeta, RARgamma) to modify gene expression and epithelial cell differentiation, reducing microcomedo formation and promoting comedone extrusion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Absorica Ld
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Altreno
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Absorica Ld
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Altreno
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Absorica Ld
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Altreno
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Absorica Ld.
No savings programs available for Altreno.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Absorica LdView full Absorica Ld profile
AltrenoView full Altreno profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.